19Varicella-zoster virus antigen kitDermaQuick VZVAdenovirus kitMLine AdenoGroup A beta-hemolytic streptococcal antigen kitMLine StrepAGlobal Presence / Activities Other than Prescription Drugs for Skin DiseasesTo respond to people’s desires to “live better,” such as the desire to live with clear skin, to live an active life, and to live in peace without pain, the Fourth Medium-Term Plan has a priority theme, “Expand business areas utilizing the strengths of the Maruho Group.” This theme is associated with business activities in areas other than prescription drugs for skin diseases. We expanded our business areas to prescription drugs other than those for skin diseases, diagnostic drugs, medical devices, and self-care. By collaborating with Group companies and partner companies with strengths not found in Maruho, we will provide the best solutions to the needs of a wide range of people, not only medical professionals, and contribute to realizing people’s desires.For prescription drugs other than those for skin diseases, Maruho is working on the early-stage introduction of candidate drugs to enhance the pipeline in the area of cancer supportive care while also searching to discover new candidate products. In the area of cancer supportive care, Maruho has contributed to improving the QOL of cancer patients with Rozex Gel for the reduction of malodor generated in cancerous cutaneous ulcers. Maruho entered into a joint research agreement with National Cancer Center Japan in October 2018, under which a joint study on new pain relief drugs for stomatitis associated with cancer treatment and examination of the possibility of their clinical application are ongoing. We will continue to develop new business areas with no exclusions, focusing on how we can properly respond to patients’ needs.Maruho launched its diagnostic drugs business in 2015 to support the care cycle through comprehensive information provision, including diagnosis necessary for treatment. Maruho currently markets DermaQuick VZV, a diagnostic kit to assist the differential diagnosis of viral skin diseases herpes zoster and varicella. Maruho has also ventured into the market of diagnostic drugs for diseases other than skin diseases with the launch of MLine StrepA in 2021, a kit to assist diagnosis of adenovirus infection and hemolytic streptococcal infection.Developing the diagnostic drugs businessIn addition to the rising life expectancy in Japan, people’s awareness about health and daily life is changing rapidly and their needs are increasingly diversifying. Maruho’s growth has been driven mainly by its prescription drug business for skin diseases. However, to continue the growth of the entire Maruho Group in the future, collaboration with Group companies and partner companies is essential. By combining strengths of all partner companies, we will venture into new businesses beyond the current operation locations and business areas.Enhancing businesses other than prescription drugs for skin diseasesExpand business areas utilizing the strengths of the Maruho Group Activities Other than Prescription Drugs for Skin DiseasesVenturing into new businesses through collaborations with Group companies and partner companies
元のページ ../index.html#21